Model-based comparative pharmacoeconomic analyses of bimatoprost 0.03% in the treatment of glaucoma or ocular hypertension in adult patients in Austria and Finland

被引：2

作者：

Poulsen, PB

Christensen, TL

Holmstrom, S

Buchholz, P

Walt, JG

机构：

[1] MUUSMANN Res & Consulting, Kolding, Denmark

[2] Allergan Pharmaceut Inc, Mougins, France

[3] Allergan Pharmaceut Inc, Ettlingen, Germany

[4] Allergan Pharmaceut Inc, Irvine, CA 92715 USA

来源：

VALUE IN HEALTH | 2003年 / 6卷 / 03期

关键词：

D O I：

10.1016/S1098-3015(10)63949-6

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：239 / 239

页数：1

共 46 条

[1] Bimatoprost 0.03% an efficacious and cost-effective choice in the treatment of glaucoma in adult patients in Austria and Finland
Poulsen, PB
Christensen, TL
Holmstrom, S
Buchholz, P
SOE 2003: XIV CONGRESS OF THE EUROPEAN SOCIETY OF OPHTHALMOLOGY, 2003, : 155 - 158
[2] A Markov modelled pharmacoeconomic analysis of bimatoprost 0.03% (Lumigan®) in the treatment of glaucoma or ocular hypertension as an alternative to filtration surgery in Italy
Vetrugno, M
Christensen, TL
Poulsen, PB
Walt, J
Holmstrom, S
VALUE IN HEALTH, 2003, 6 (06) : 628 - 628
[3] Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension
Cantor, LB
WuDunn, D
Cortes, A
Hoop, J
Knotts, S
SURVEY OF OPHTHALMOLOGY, 2004, 49 : S12 - S18
[4] Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension
Cantor, LB
Wudunn, D
Cortes, A
Hoop, J
Knotts, S
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 : U511 - U511
[5] Comparative effectiveness of bimatoprost 0.03% preservative free for the treatment of open-angle glaucoma and ocular hypertension
Brereton, N.
Stradwick, S.
Harvey, B.
Shergill, C.
Patel, V.
Wong, W.
ACTA OPHTHALMOLOGICA, 2013, 91
[6] Retrospective Analysis of Switching Bimatoprost 0.01% to Bimatoprost 0.03% in Patients with Various Types of Glaucoma and Ocular Hypertension
Xu, Kai Man
Cho, Ryan
Chan, Toby Yiu Bong
CLINICAL OPHTHALMOLOGY, 2022, 16 : 2385 - 2390
[7] A model-based pharmacoeconomic analysis of brimonidine tartate 0.2% as an adjunctive therapy to beta-blockers in the treatment of glaucoma or ocular hypertension in adult patients in Norway
Christensen, TL
Poulsen, PB
Holmstrom, S
Maeland, K
Walt, JG
VALUE IN HEALTH, 2003, 6 (03) : 238 - 238
[8] COMPARISON OF THE IOP -LOWERING EFFICACY OF BIMATOPROST 0.03% AND TRAVOPROST 0.004% IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION
L.B.Cantor
国际眼科杂志, 2003, (01) : 53 - 54
[9] IOP-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension
Cantor, LB
Hoop, J
Morgan, L
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46
[10] Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension
Noecker, R.
BRITISH JOURNAL OF OPHTHALMOLOGY, 2006, 90 (11) : 1336 - 1337

← 1 2 3 4 5 →